All In Biotech

Drug Trial Radar · NCT00641537

CLARITY Extension Study

A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)

Last checked: Nov 20, 2026Latest source record: Dec 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 867 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

867

Actual

Start

Feb 29, 2008

Primary completion

Dec 31, 2011

Study completion Dec 31, 2011

Sponsor

Sponsor type
Industry
First posted
Mar 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • CladribineDrug

    Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.

  • PlaceboDrug

    Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.

  • CladribineDrug

    Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.

  • CladribineDrug

    Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.

  • PlaceboDrug

    Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic ToxicityTime frame: Baseline up to Week 120
  2. Safety Population: Mean Change From Baseline in Absolute Lymphocyte Count, Platelet, Neutrophils and Leukocytes at Week 120Time frame: Baseline, Week 120
  3. Safety Population: Mean Change From Baseline in Hemoglobin at Week 120Time frame: Baseline, Week 120
  4. Safety Population: Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase at Week 120Time frame: Baseline, Week 120
  5. Safety Population: Mean Change From Baseline in Bilirubin at Week 120Time frame: Baseline, Week 120
  6. Safety Population: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to Week 120
  7. SAFUP Analysis Set: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to Week 120
  8. Safety Population: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and MalignanciesTime frame: Baseline up to Week 120
  9. SAFUP Analysis Set: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and MalignanciesTime frame: Baseline up to Week 120
  10. Safety Population: Time to First Grade 3 or 4 Hematological Toxicity and Liver ToxicityTime frame: Baseline up to Week 120
  11. Safety Population: Median Time to Recovery From Grade 3 or 4 Hematological and Hepatic ToxicityTime frame: Baseline up to Week 120
  12. Safety Population: Mean Time to Recovery From Grade 3 or 4 Hematological and Liver ToxicityTime frame: Baseline up to Week 120
  13. Safety Population: Median Time to Nadir of Absolute Lymphocyte CountTime frame: Baseline up to Week 120
  14. Safety Population: Mean Time to Nadir of Absolute Lymphocyte CountTime frame: Baseline up to Week 120
  15. Safety Population: Mean Time to Recovery From Nadir of Absolute Lymphocyte Count to Normal ValueTime frame: Baseline up to Week 120
  16. Safety Population: Mean Change in Corrected QT (QTc) Interval From BaselineTime frame: Baseline, Week 5, 48, 52 and 96

Locations

116 sites in 31 countries. Site status is shown where the registry gives one.

  • Research Site

    Boulder, Colorado

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Northbrook, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Henderson, Nevada

  • Research Site

    Newark, New Jersey

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Medford, Oregon

  • Research Site

    Seattle, Washington

  • Research Site

    Tacoma, Washington

  • Research Site

    Charleston, West Virginia

  • Research Site

    Camperdown, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Victoria, Australia

  • Research Site

    Linz, Austria

  • Research Site

    Diepenbeek, Belgium

  • Research Site

    Esneux, Belgium

  • Research Site

    Recife, Brazil

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Rousse, Bulgaria

  • Research Site

    Shuman, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Zagora, Bulgaria

  • Research Site

    Burnaby, Canada

  • Research Site

    Greenfield Park, Canada

  • Research Site

    Ottawa, Canada

  • Research Site

    Québec, Canada

  • Research Site

    Karlovac, Croatia

  • Research Site

    Sisak, Croatia

  • Research Site

    Split, Croatia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Olomouc, Czechia

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.